Deutsche Bank analyst David Hoang initiated coverage of Axsome Therapeutics (AXSM) with a Buy rating and $176 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $150 from $110 at Leerink
- Analyst Upgrades Axsome to Buy Amid Key Settlement with Teva and Raised Price Target
- Shares in Biopharma Firm Axsome Surge Over 20% After Settling Teva Patent Dispute
- Axsome Therapeutics: Strategic Legal Resolution and Growth Potential Propel Buy Rating
- Morning Movers: Aluminum, steel stocks gain on planned 25% tariffs on imports